Juvenile Idiopathic Arthritis (JIA) - Uveitis

Approximately 10-30% of children with JIA develop uveitis, which tends to affect eyes over a long time and mainly involves the front part of the eye. This can lead to visual loss, cataracts, increased pressure, and blindness.

In the early stages there are often no symptoms and there is currently no way to predict who will develop uveitis. There are a number of treatments for uveitis including eye drops, immunosuppressive drugs, and steroids. The EATC4Children is actively engaged in investigating new treatments for uveitis.


The aim of this trial is to determine if Tocilizumab works in treating JIA-Uveitis in children who have not gotten better with Methotrexate or anti-TNF (Adalimumab) treatments. The trial (funded by ARUK) is running in partnership with Roche who provide Tocilizumab. It has recently completed recruitment and is in the follow up stages (CI’s: A. Ramanan and M. Beresford).

CLUSTER (Childhood Arthritis and associated uveitis: stratification through endotypes and mechanism)

The CLUSTER consortium aims to identify the best way to target the right drug to the right child at the right time, in children with JIA and uveitis. The project began in July 2018 and the EATC4Children is leading two of the five workstreams: JIA-uveitis and Industry (Co-CI’s:M. Beresford, A. Ramanan). Click the link below to be directed to their website.

Cluster Logo

Back to: Experimental Arthritis Treatment Centre for Children